Takahashi, Kiyohiko
Nakamura, Akinobu http://orcid.org/0000-0002-8192-0006
Miyoshi, Hideaki
Nomoto, Hiroshi
Kitao, Naoyuki
Omori, Kazuno
Yamamoto, Kohei
Cho, Kyu Yong
Terauchi, Yasuo
Atsumi, Tatsuya
Article History
Received: 10 January 2018
Accepted: 13 April 2018
First Online: 1 May 2018
Competing Interests
: A.N. received honoraria for lectures from Sanofi, Mitsubishi Tanabe Pharma, Daiichi Sankyo, Eli Lilly Japan, MSD, Novo Nordisk Pharma, Novartis Pharma, AstraZeneca, Takeda Pharmaceutical, Astellas, Kowa Pharmaceutical, Ono, Dainippon Sumitomo Pharma, Nippon Boehringer Ingelheim, Kissei Pharmaceutical, and Taisho Toyama Pharmaceutical; and obtained research support from Sanofi, Mitsubishi Tanabe Pharma, MSD, Novo Nordisk Pharma, Novartis Pharma, AstraZeneca, Ono, and Taisho Toyama Pharmaceutical. H.M. received honoraria for lectures from Astellas Pharma, AstraZeneca, Dainippon Pharma, Eli Lilly, Kissei, Mitsubishi Tanabe Pharma, MSD, Novo Nordisk Pharma, and Sanofi; and has received research funding from Astellas Pharma, AstraZeneca, Eli Lilly, and Mitsubishi Tanabe Pharma. Y.T. received honoraria for speakers bureau from Astellas Pharma, AstraZeneca K.K., Bayer Yakuhin, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eli Lilly Japan K.K., Kowa Pharmaceutical, Merck Sharp & Dohme K.K., Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, Novo Nordisk Pharma, Ono Pharmaceutical, Sanwa Kagaku Kenkyusho, Sanofi K.K., Shionogi & Co, Taisho Toyama Pharmaceutical, and Takeda Pharmaceutical; and grants from Astellas Pharma, Daiichi Sankyo, Dainippon Sumitomo Pharma, MSD K.K., Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, Ono Pharmaceutical, Sanofi K.K., and Takeda Pharmaceutical. T.A. received honoraria for lectures from Mitsubishi Tanabe Pharma, Chugai Pharmaceutical, Astellas Pharma, Takeda Pharmaceutical, Pfizer, and AbbVie; and received research funding from Astellas Pharma, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical, Daiichi Sankyo, and Otsuka Pharmaceutical. The other authors have no potential conflicts of interest to declare.